Articles tagged with 'DocCheck-EN' | Bayer

Newsroom Bayer (DocCheck-EN)

2024
February
21,
2024
| 14:00 PM Europe/Amsterdam
New research and clinical development data on investigational compound gadoquatrane, Bayer’s novel investigational MRI contrast agent in late-stage clinical development, as well as its approved MR contrast agent gadobutrol to be presented at ECR 2024...
Read more
February
06,
2024
| 08:29 AM Europe/Amsterdam
VVD-130850 is an investigational oral small molecule inhibitor of STAT3 transcription factor developed for treatment of advanced solid and hematologic tumors as a single agent and in combination with checkpoint inhibitors / Innovative clinical candid...
Read more
January
24,
2024
| 08:29 AM Europe/Amsterdam
Study data are now under review by the regulatory body in China / Submission refers to treatment of wet age-related macular degeneration based on the phase III study PULSAR, that demonstrated unprecedented durability results with treatment intervals ...
Read more
January
18,
2024
| 08:29 AM Europe/Amsterdam
Japanese Ministry of Health, Labour and Welfare (MHLW) approved new Eylea 8 mg (aflibercept 8 mg) for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) based on positive results from clinical trials PULSAR and...
Read more
January
17,
2024
| 14:29 PM Europe/Amsterdam
Bayer continues to focus on advancing prostate cancer care, presenting additional data on darolutamide from the ARASENS trial and radium-223 dichloride from the REASSURE trial
Read more
January
08,
2024
| 10:29 AM Europe/Amsterdam
New Phase II study NIRVANA aims to explore efficacy and safety of investigational compound elinzanetant as a non-hormonal treatment for sleep disturbances associated with menopause (SDM) / SDM may have an impact on women’s quality of life, work produ...
Read more
January
08,
2024
| 08:59 AM Europe/Amsterdam
The European Commission has granted marketing authorization in the European Union (EU) for new Eylea™ 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) / Aflibercep...
Read more
2023
November
22,
2023
| 13:59 PM Europe/Amsterdam
First presentation of Phase II data for the development compound gadoquatrane, Bayer’s investigational MRI contrast agent, at RSNA 2023 / Publication of a novel health economic model, analyzing cost effectiveness and capacity needs of supplemental sc...
Read more
November
10,
2023
| 14:58 PM Europe/Amsterdam
Recommendation by Committee for Medicinal Products for Human Use (CHMP) based on positive results from PULSAR clinical trial in neovascular (wet) age-related macular degeneration (nAMD) and PHOTON trial in diabetic macular edema (DME) / If approved b...
Read more
November
06,
2023
| 08:59 AM Europe/Amsterdam
New study includes patients aged ≥65 years with atrial fibrillation (AF) at high risk for ischemic stroke or systemic embolism who are deemed ineligible for oral anticoagulant (OAC) treatment due to increased risk of bleeding / OCEANIC-AFINA, the lat...
Read more
November
02,
2023
| 14:59 PM Europe/Amsterdam
Late-breaking data from an analysis of FIDELITY show early albuminuria reduction after four months of finerenone treatment has an impact on long-term kidney outcomes / Based on a patient cohort of more than 12,500 individuals, this comprehensive anal...
Read more
October
12,
2023
| 08:29 AM Europe/Amsterdam
Bayer's focus remains on advancing prostate cancer care with darolutamide, supported by additional ARASENS and ARAMIS trial data evaluating prostate-specific antigen (PSA) outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) and composite...
Read more
September
28,
2023
| 08:29 AM Europe/Amsterdam
Presentations at EURETINA capture 60-week data, a key secondary endpoint, and two-year data (96-week) from the pivotal PULSAR and PHOTON clinical trials that provide insights into durability of extended treatment intervals as well as efficacy and saf...
Read more
September
21,
2023
| 14:29 PM Europe/Amsterdam
Strategic expansion of Bayer’s portfolio in breast imaging / Companies to deliver innovative solutions on contrast-enhanced mammography (CEM) to imaging facilities / Collaboration to include education and hands-on training to support the safe and eff...
Read more
September
18,
2023
| 08:59 AM Europe/Amsterdam
Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform / First-in-cl...
Read more
August
24,
2023
| 10:29 AM Europe/Amsterdam
Three new investigator-sponsored collaborative studies are funded by Bayer and will evaluate the efficacy and safety of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), in approximately 9,300 heart failure (HF) pati...
Read more
August
10,
2023
| 12:59 PM Europe/Amsterdam
Results from PULSAR demonstrate long term efficacy of aflibercept 8 mg with extended dosing intervals reaching up to 24 weeks and vision improvements comparable to Eylea™ (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients randomize...
Read more
June
29,
2023
| 08:29 AM Europe/Amsterdam
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to EyleaTM (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients assigned to a 16-week dosing regimen at baseline rec...
Read more
June
27,
2023
| 08:29 AM Europe/Amsterdam
Gadoquatrane is a highly stable contrast agent for magnetic resonance imaging (MRI) featuring high relaxivity with the potential for a substantially lower gadolinium (Gd) dose / QUANTI clinical development program includes two Phase III studies in ad...
Read more
June
22,
2023
| 08:29 AM Europe/Amsterdam
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) / CKD affects up to 40% of people with T1D / A quarte...
Read more
June
21,
2023
| 08:29 AM Europe/Amsterdam
Partnership will enhance clinical adoption of artificial intelligence (AI) in medical imaging  / AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity of radiology interventions...
Read more
June
15,
2023
| 08:59 AM Europe/Amsterdam
New post hoc analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will validate a model predicting the risk of chronic kidney disease (CKD) progression in adults at all stages of CKD / Update on FINEGUST study, descri...
Read more
June
01,
2023
| 13:59 PM Europe/Amsterdam
Phase II/III study VALOR will assess efficacy, safety and pharmacokinetics of vericiguat in pediatric patients / VALOR is the pivotal study in pediatric heart failure with vericiguat
Read more
May
25,
2023
| 13:59 PM Europe/Amsterdam
Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 ...
Read more
May
17,
2023
| 13:59 PM Europe/Amsterdam
Chinese National Medical Products Administration granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase II...
Read more
May
10,
2023
| 09:59 AM Europe/Amsterdam
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macula...
Read more
May
09,
2023
| 08:59 AM Europe/Amsterdam
Poster presentation from the REALISE study, a real-world evidence analysis evaluating the status of treatment of vasomotor symptoms (VMS) and symptom burden in women taking adjuvant endocrine therapy (AET) after breast cancer, showing a need for new ...
Read more
May
02,
2023
| 09:00 AM Europe/Amsterdam
Poster presentation on the EMPOWER study, a qualitative analysis from interviews with menopausal women, shows the importance of vasomotor symptoms (VMS), as well as potential treatment side effects on the women’s treatment decisions / Poster presenta...
Read more
April
17,
2023
| 12:59 PM Europe/Amsterdam
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg / In total, 18 present...
Read more
April
11,
2023
| 12:59 PM Europe/Amsterdam
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 / New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs o...
Read more